
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
PT VIDEO: The non-pruritic rash spread from his chest over 3d; no response to prednisone. What do you suspect?